# Medical Supply Chain Resiliency Act: What It Actually Does

During the COVID-19 pandemic, hospitals and clinics across America struggled to get basic medical supplies—masks, ventilators, medications, and protective equipment. The problem wasn't just high demand; it was that the United States relied too heavily on a small number of countries for these critical goods, and when those countries restricted exports to keep supplies for themselves, Americans suffered. This bill tries to fix that problem by creating a new type of trade agreement focused specifically on medical products.

Here's what the bill does in practical terms: It gives the President power to negotiate special trade deals with countries that agree to be reliable partners in medical supply chains. These aren't ordinary trade agreements. Instead of covering everything from cars to agriculture, these "trusted trade partner agreements" focus only on medical goods—drugs, vaccines, medical devices, and the ingredients used to make them. When the President makes one of these deals with another country, both nations would lower or eliminate tariffs and other barriers on medical products. The idea is that if trade flows more freely, companies will have more options for where to source supplies, and countries won't hoard medical goods during emergencies.

But the bill includes important safeguards. Before the President can make such a deal, Congress gets advance notice and a chance to review it. The bill requires the President to prove that a potential partner country actually deserves the label "trusted"—meaning it protects intellectual property, follows the rule of law, doesn't discriminate unfairly against American companies, and has shown it won't cut off medical supplies during health crises. Once an agreement is in place, the Trade Representative must keep monitoring whether the partner country is actually living up to its commitments. If a country breaks the deal, the President can suspend the agreement or take other action to protect American interests.

The practical impact for everyday Americans could be significant. If this works as intended, medical supply chains would become more resilient, meaning fewer shortages during future pandemics or emergencies. Prices for some medical products might decrease if competition increases and tariffs drop. However, there's a potential downside: if manufacturing shifts to other countries, some American medical manufacturing jobs could be affected. The bill tries to address this by only partnering with countries that meet strict standards, but the long-term employment effects remain uncertain.

Medical Supply Chain Resiliency Act

Steel, Michelle

Medical Supply Chain Resiliency ActThis bill authorizes actions to facilitate trade in medical goods (i.e., medical devices, pharmaceutical goods, or inputs for such devices or goods).Specifically, the bill authorizes the President to (1) negotiate, enter into, and enforce a trusted trade partner agreement with a country or countries with respect to medical goods; and (2) proclaim a modification of any existing duty, a continuance of existing duty-free or excise treatment, or additional duties to carry out the trade agreement. These actions may only be taken if the President determines, based on specified considerations, that the reciprocal elimination of existing duties or other import restrictions with respect to medical goods would contribute to&nbsp;U.S. national security and public health.&nbsp;A trusted trade partner agreement may include certain provisions, such as those to (1) reduce or eliminate duties, quotas, or other trade barriers; (2) diversify and expand supplier networks to secure a reliable supply of medical goods; and (3) harmonize regulatory procedures.Not later than 60 days before initiating negotiations with a trusted trade partner, the President must submit written notice to Congress. The bill requires congressional consultation and review of these trade agreements. A trade agreement shall not take effect if, during the required review period, Congress enacts a joint resolution of disapproval.The Office of the&nbsp;U.S. Trade Representative must monitor compliance by a trusted trade partner with the trade agreement's commitments and obligations. Further, the President may take certain actions in response to a failure to comply.